Bristol Myers axes German launch of new cancer drug, citing pricing hurdles

Bristol Myers axes German launch of new cancer drug, citing pricing hurdles

Source: 
Endpoints
snippet: 

Following its European approval last September, Bristol Myers Squibb has decided not to launch Opdualag, an infusion of the pharma giant’s Opdivo and new antibody relatlimab, in Germany due to pricing pressures. The drug won approval to treat advanced melanoma in adults and adolescents aged 12 years and older.